{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:19:41Z","timestamp":1764587981524,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11033-019-04706-w","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T13:02:51Z","timestamp":1553259771000},"page":"2523-2528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Vincristine combination with Ca+2 channel blocker increase antitumor effects"],"prefix":"10.1007","volume":"46","author":[{"given":"Ali","family":"Taghizadehghalehjoughi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6575-6149","authenticated-orcid":false,"given":"Selma","family":"Sezen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Hacimuftuoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medine","family":"G\u00fcll\u00fcce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"issue":"1","key":"4706_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1021\/mp100249x","volume":"8","author":"Y Zhang","year":"2011","unstructured":"Zhang Y et al (2011) Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. Mol Pharm 8(1):162\u2013175","journal-title":"Mol Pharm"},{"issue":"6","key":"4706_CR2","first-page":"2011","volume":"30","author":"Y Aksoy","year":"2010","unstructured":"Aksoy Y (2010) Ways for overcoming drug resistance in cancer: designing new drugs: invited commentary. Turkiye Klinikleri Tip Bilimleri Dergisi 30(6):2011\u20132016","journal-title":"Turkiye Klinikleri Tip Bilimleri Dergisi"},{"issue":"10","key":"4706_CR3","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/ijc.28334","volume":"134","author":"A Milan","year":"2014","unstructured":"Milan A et al (2014) Arterial hypertension and cancer. Int J Cancer 134(10):2269\u20132277","journal-title":"Int J Cancer"},{"key":"4706_CR4","first-page":"19","volume":"107","author":"F Yesilyurt","year":"2018","unstructured":"Yesilyurt F, Taghizadehghalehjoughi A, Hacimuftuoglu A (2018) ACTH and amlodipine effects on neuroblastoma and cortical neurons. Neuroendocrinology 107:19\u201319","journal-title":"Neuroendocrinology"},{"key":"4706_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/2398212818794805","author":"AC Dolphin","year":"2018","unstructured":"Dolphin AC (2018) Voltage-gated calcium channels: their discovery, function and importance as drug targets. Brain Neurosci Adv. \n                    https:\/\/doi.org\/10.1177\/2398212818794805","journal-title":"Brain Neurosci Adv"},{"issue":"7","key":"4706_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","volume":"11","author":"I Sipahi","year":"2010","unstructured":"Sipahi I et al (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11(7):627\u2013636","journal-title":"Lancet Oncol"},{"issue":"10","key":"4706_CR7","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/1440-1681.12803","volume":"44","author":"LF Carvalho","year":"2017","unstructured":"Carvalho LF, Silva AMF, Carvalho AA (2017) The use of antioxidant agents for chemotherapy-induced peripheral neuropathy treatment in animal models. Clin Exp Pharmacol Physiol 44(10):971\u2013979","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"4706_CR8","volume-title":"Molecular mechanisms of vincristine and paclitaxel resistance in mcf-7 cell line","author":"M kars Demirel","year":"2008","unstructured":"kars Demirel M (2008) Molecular mechanisms of vincristine and paclitaxel resistance in mcf-7 cell line. Middle East Technical University, Ankara"},{"issue":"2","key":"4706_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0092-8674(02)00625-6","volume":"108","author":"RW Johnstone","year":"2002","unstructured":"Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108(2):153\u2013164","journal-title":"Cell"},{"issue":"1","key":"4706_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2559.2008.03070.x","volume":"53","author":"A Gregorio","year":"2008","unstructured":"Gregorio A et al (2008) Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule. Histopathology 53(1):73\u201380","journal-title":"Histopathology"},{"key":"4706_CR11","volume-title":"Principles and practice of pediatric oncology","author":"PA Pizzo","year":"2015","unstructured":"Pizzo PA, Poplack DG (2015) Principles and practice of pediatric oncology. Lippincott Williams & Wilkins, Philadelphia"},{"issue":"1","key":"4706_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.24659","volume":"80","author":"N Ratner","year":"2016","unstructured":"Ratner N et al. (2016) The \u201cneuro\u201d of neuroblastoma: neuroblastoma as a neurodevelopmental disorder. Ann Neurol 80(1):13\u201323","journal-title":"Ann Neurol"},{"issue":"2","key":"4706_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5505\/tjb.2012.57966","volume":"37","author":"Z Erbayraktar","year":"2012","unstructured":"Erbayraktar Z et al (2012) The role of p14ARF methylation in neuroblastoma minimal residual disease. Turkish J Biochem Turk Biyokimya Dergisi 37(2):129\u2013138","journal-title":"Turkish J Biochem Turk Biyokimya Dergisi"},{"issue":"4","key":"4706_CR14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/pr.114.009654","volume":"67","author":"GW Zamponi","year":"2015","unstructured":"Zamponi GW et al (2015) The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev 67(4):821\u2013870","journal-title":"Pharmacol Rev"},{"issue":"19","key":"4706_CR15","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1056\/NEJM199911043411907","volume":"341","author":"DR Abernethy","year":"1999","unstructured":"Abernethy DR, Schwartz JB (1999) Calcium-antagonist drugs. N Engl J Med 341(19):1447\u20131457. \n                    https:\/\/doi.org\/10.1056\/NEJM199911043411907","journal-title":"N Engl J Med"},{"issue":"21","key":"4706_CR16","first-page":"7291","volume":"63","author":"MS Kim","year":"2003","unstructured":"Kim MS et al (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Can Res 63(21):7291\u20137300","journal-title":"Can Res"},{"key":"4706_CR17","first-page":"16","volume":"33","author":"T Groh","year":"2012","unstructured":"Groh T et al (2012) Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells. Neuroendocrinol Lett 33:16\u201324","journal-title":"Neuroendocrinol Lett"},{"issue":"1","key":"4706_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3892\/ijo.2015.2996","volume":"47","author":"T Groh","year":"2015","unstructured":"Groh T et al (2015) The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells. Int J Oncol 47(1):343\u2013352","journal-title":"Int J Oncol"},{"issue":"1","key":"4706_CR19","first-page":"21","volume":"10","author":"NM Emin","year":"2019","unstructured":"Emin NM, Taghizadehghalehjoughi A (2019) Should we use remifentanil in every dose and every case? J Clin Anal Med 10(1):21\u201325","journal-title":"J Clin Anal Med"},{"issue":"2","key":"4706_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00268-012-1837-0","volume":"37","author":"DA Cozzi","year":"2013","unstructured":"Cozzi DA et al (2013) Long-term follow-up of the \u201cwait and see\u201d approach to localized perinatal adrenal neuroblastoma. World J Surg 37(2):459\u2013465. \n                    https:\/\/doi.org\/10.1007\/s00268-012-1837-0","journal-title":"World J Surg"},{"key":"4706_CR21","first-page":"R25","volume":"307","author":"A Fleckenstein","year":"1969","unstructured":"Fleckenstein A et al (1969) A new group of competitive Ca antagonists with highly potent inhibitory effects on excitation-contraction coupling in mammalian myocardium. Pflugers Arch Eur J Physiol 307:R25","journal-title":"Pflugers Arch Eur J Physiol"},{"issue":"10","key":"4706_CR22","first-page":"662","volume":"41","author":"RC Khokhani","year":"1993","unstructured":"Khokhani RC et al (1993) Amlodipine in mild and moderate hypertension: initial Indian experience. J Assoc Physicians India 41(10):662\u2013663","journal-title":"J Assoc Physicians India"},{"issue":"6","key":"4706_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/BF00499454","volume":"12","author":"M Pahor","year":"1996","unstructured":"Pahor M et al (1996) Trends of the characteristics and appropriateness of admissions to acute geriatric and medical wards in Italy from 1988 through 1993. Gruppo Italiano di Farmacovigilanza nell\u2019Anziano\u2013GIFA. Eur J Epidemiol 12(6):563\u2013571","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"4706_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","volume":"12","author":"S Bangalore","year":"2011","unstructured":"Bangalore S et al (2011) Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 12(1):65\u201382","journal-title":"Lancet Oncol"},{"issue":"7","key":"4706_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S1470-2045(10)70142-X","volume":"11","author":"SE Nissen","year":"2010","unstructured":"Nissen SE (2010) Angiotensin-receptor blockers and cancer: urgent regulatory review needed. Lancet Oncol 11(7):605\u2013606","journal-title":"Lancet Oncol"},{"issue":"12","key":"4706_CR26","first-page":"3670","volume":"50","author":"GH Mickisch","year":"1990","unstructured":"Mickisch GH et al (1990) Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 50(12):3670\u20133674","journal-title":"Cancer Res"},{"issue":"3","key":"4706_CR27","first-page":"265","volume":"5","author":"ML Sezzi","year":"1985","unstructured":"Sezzi ML et al (1985) Effects of a calcium-antagonist (flunarizine) on cancer cell movement and phagocytosis. Anticancer Res 5(3):265\u2013271","journal-title":"Anticancer Res"},{"issue":"4","key":"4706_CR28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.4103\/0972-5229.45083","volume":"12","author":"S Ghosh","year":"2008","unstructured":"Ghosh S, Sircar M (2008) Calcium channel blocker overdose: experience with amlodipine. Indian J Crit Care Med 12(4):190\u2013193","journal-title":"Indian J Crit Care Med"},{"issue":"1","key":"4706_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF03160947","volume":"4","author":"MT Sim","year":"2008","unstructured":"Sim MT, Stevenson FT (2008) A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose. J Med Toxicol 4(1):25\u201329","journal-title":"J Med Toxicol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-04706-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-019-04706-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-019-04706-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:09:18Z","timestamp":1584749358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-019-04706-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["4706"],"URL":"https:\/\/doi.org\/10.1007\/s11033-019-04706-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2019,3,22]]},"assertion":[{"value":"27 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}